Free Trial
OTCMKTS:ALPMY

Astellas Pharma 4/25/2025 Earnings Report

Astellas Pharma logo
$9.80 +0.10 (+0.98%)
As of 05/30/2025 04:00 PM Eastern

Astellas Pharma EPS Results

Actual EPS
$0.27
Consensus EPS
$0.15
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Astellas Pharma Revenue Results

Actual Revenue
$3.22 billion
Expected Revenue
$3.02 billion
Beat/Miss
Beat by +$205.66 million
YoY Revenue Growth
N/A

Astellas Pharma Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Astellas Pharma's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules.

Conference Call Resources

Astellas Pharma Earnings Headlines

This document could hand you a shot at $915 every single weekend!
Something fascinating happens in the options market when most traders aren't paying attention… While everyone else collects standard daily premiums Monday through Friday... There's a special opportunity to target TRIPLE premiums just for holding positions over the weekend. Think about that... Most traders get one day's worth of premium for their trades. But by entering right before the weekend, when everything works out, you could collect THREE days worth - even though markets are closed for two of them. Thanks to a special discovery by a Wall Street legend who helped manage a $1.7 trillion firm – regular folks like you can now target extra cash from the markets on weekends… Just like he showed his small group of traders on December 20th with KO... A quick 2-minute setup Friday afternoon… Head out for the weekend... Monday morning? An extra $1,111 sitting in the account (with a $5k starting stake).
See More Astellas Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email.

About Astellas Pharma

Astellas Pharma (OTCMKTS:ALPMY) manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

View Astellas Pharma Profile

More Earnings Resources from MarketBeat